Please login to the form below

Not currently logged in
Email:
Password:

Regeneron

This page shows the latest Regeneron news and features for those working in and with pharma, biotech and healthcare.

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

Amgen also reported data at ASH on another BiTE candidate called AMG 330 which targets CD33, the same target as Regeneron’s REGN1979 which posted results in lymphoma earlier during the

Latest news

More from news
Approximately 46 fully matching, plus 117 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Ophthalmology. Ophthalmology is dominated by a small number of the same therapies marketed by different companies in different regions; Regeneron, Bayer and Santen all market Eylea, whereas Novartis and Roche market ... Regeneron remains the leading

  • Deal Watch October 2016 Deal Watch October 2016

    330. Ocular Therapeutics (US). Regeneron (US). Licence collaboration. Hydrogel sustained release aflibercept (Eylea) for wet macular degeneration.

  • Deal Watch September 2016 Deal Watch September 2016

    4, 325. Regeneron / Teva. Licence. Fasinumab in P3 for osteoarthritis pain, upfront payment $250m [excludes rights to Japan, Korea and other Asian markets].

  • Deal Watch April 2016 Deal Watch April 2016

    with deals by Regeneron, Madrigal and Tobira). ... 265 . Intellia (US). Regeneron (US). Co-development &co-commercialisation. Discovery stage CRISPR/Cas platform for treatments of liver disease.

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration &licence. $134. Regeneron/ Bayer. Ophthalmology combination therapy: nesvacumab (Ang2 antibody) and aflibercept (VEGF trap).

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest appointments

  • Tiziana Life Sciences appoints clinical sciences VP Tiziana Life Sciences appoints clinical sciences VP

    Prior to this, Dr Evans held a number of scientific leadership positions while at Amgen, Johnson &Johnson and Regeneron.

  • Regeneron taps Pfizer for CFO Regeneron taps Pfizer for CFO

    Robert Landry succeeds Murray Goldberg. Former Pfizer senior VP Robert Landry has joined Regeneron as senior VP, finance, and will later take over as chief financial officer. ... We are extremely fortunate that Murray will stay at Regeneron through 2014

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics